Authors
Paula Raquel Pujols-León, Sofía Méndez-Blanco, Lucía Ordieres-Ortega, Marina López-Rubio, Francisco Galeano-Valle, Pablo Demelo-Rodríguez
Published in
Autoimmunity reviews. Pages 104245. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a chronic inflammatory disorder associated with an increased risk of venous thromboembolism (VTE), particularly during active disease, hospitalization or after surgery. The risk of VTE is approximately two to three times higher in patients with IBD than in the general population. The underlying mechanisms are multifactorial and include systemic inflammation, platelet activation, endothelial dysfunction, and alterations in the intestinal microbiota. Diagnosis requires a high index of clinical suspicion. D-dimer may help exclude VTE in patients with low pretest probability but is frequently elevated during active inflammation and therefore lacks specificity. Pharmacological thromboprophylaxis, preferably with low-molecular-weight heparin, is recommended for hospitalized patients with IBD, whereas the choice and duration of therapeutic anticoagulation should be individualized according to thrombotic and bleeding risk. This review summarizes current evidence on the epidemiology, pathophysiology, diagnosis, prevention and management of VTE in IBD, with particular focus on recent population-based incidence data, phase-dependent thrombotic risk post-discharge prophylaxis and individualized anticoagulant selection.
PMID:
43039205
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0